James J. Mullen III

Partner | San Diego

jmullen@mofo.com | (858) 720-7940

(858) 720-7940

Obtaining strong intellectual property protection is pivotal for success in the biotechnology marketplace. I focus on securing robust, commercially relevant IP protection for my clients in the most efficient manner possible.

James combines his scientific experience with his legal training in his practice to craft commercially relevant solutions for his clients’ intellectual property challenges. He is the founder and head of MoFo’s Antibody Patent Group and leads the Patent Group in the San Diego office.

As a patent prosecutor, James is well versed in obtaining focused patent protection that provides a commercial advantage in the marketplace. Prosecution is only one aspect of his practice; he also has experience in conducting intellectual property due diligence studies on both the buy and sell sides for acquisitions and funding purposes. He also provides counseling about infringement issues and post–issuance proceedings, including inter partes review and reexamination proceedings for market–leading biotechnology and pharmaceutical companies, as well as small to mid–size life sciences entities.

James brings a history of industry experience to his practice, applying an insider’s understanding of the scientific development process and the challenges that companies face in crafting and executing solid patent strategies for his clients. Before graduate school and law school, James worked in various laboratories: at Hybritech, Inc., a pioneer in the development of monoclonal antibodies, and at the Research Institute of Scripps Clinic. He holds a Ph.D. in biomedical sciences from the University of Texas and a bachelor’s degree in biochemistry and cellular biology from the University of California San Diego.

He counsels clients that are pursuing inventions in a variety of biotechnology–related areas, including molecular diagnostics, clean technology, cancer therapeutics and diagnostics, infectious disease therapeutics, and small molecule screening protocols, as well as those seeking protection for novel nucleic acid and amino acid sequence protection.

Show More



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.